Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

NCT03298412 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Early Closure due to rare patient population

Conditions

High-risk Diffuse Large B-cell Lymphoma

Interventions

DRUG: Blinatumomab

Sponsor

Amgen